Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.

Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.

HIV-1/HAART-associated lipodystrophy syndrome (HALS) has been associated with exposure to stavudine (d4T) through mitochondrial dysfunction. We performed a 48-week study to assess the effects of switching from d4T to raltegravir (RAL) on metabolic and fat molecular parameters of patients with HALS....

Full description

Bibliographic Details
Main Authors: Pere Domingo, María del Mar Gutierrez, José Miguel Gallego-Escuredo, Ferran Torres, Gracia María Mateo, Joan Villarroya, Ignacio de los Santos, Joan Carles Domingo, Francesc Villarroya, Luis Del Rio, Vicente Estrada, Marta Giralt
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3935839?pdf=render

Internet

http://europepmc.org/articles/PMC3935839?pdf=render

Similar Items